# TRex Bio Prices IPO at $14, Targets $117 Million Gross

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/28787
Published: 2026-10-09T07:32:42.000Z
Updated: 2026-10-09T07:32:42.000Z
Section: Business

> The clinical-stage biotechnology company is offering 8.33 million shares and expects approximately $116.7 million in gross proceeds.

TRex Bio, Inc. (TRXB) set its initial public offering price at $14 per share, with the clinical-stage biotechnology company seeking approximately $116.7 million in gross proceeds.

The offering covers 8.33 million shares. TRex Bio develops immunoregulatory medicines.

The company’s stock is expected to begin trading on Nasdaq Global.